AP NEWS

MedAutonomic Undertakes the First Digestive Endoscopic Implant of a Brain Neuromodulation Device in a Human

September 18, 2018

CONCORD, Calif.--(BUSINESS WIRE)--Sep 18, 2018--MedAutonomic, a Silicon Valley and Venice, Italy based medtech company has successfully implanted a brain neuromodulation device, the Phoenix, into the stomach wall of a human through an innovative digestive endoscopic procedure. The Phoenix is a bioelectric medicine that is powered without a battery. It sends signals to the brain ( the limbic system ) to reset an imbalance in the Autonomic Nervous System with the aim to treat functional diseases such as type-2 diabetes, hypertension, and gastroesophageal reflux disease (GERD).

According to MedAutonomic president Dr. Valerio Cigaina, who is leading the research, “Our initial results of the first human implant of the Phoenix represent an important milestone for our company. The outpatient procedure using a gastric endoscope has been perfected, and we are able to implant our device without surgery in less than ten minutes. We are pleased to be the first to insert a diagnostic and/or therapeutic device in the gastric wall in a minimally invasive way, with the device perfectly tolerated over the long term. The Phoenix is sending a signal to the brain, which is confirmed by heart rate variability (HRV).”

“The technology that we have developed to generate power without a battery to send a signal to the brain is important,” said Paolo Fabris, chief executive officer of MedAutonomic. “We are able to harvest energy from the body, so the device can remain in the stomach wall without the need of a battery. Now that we have successfully implanted the Phoenix into the stomach of a human, we have taken a further step in developing a promising therapy for the metabolic syndrome. Our next efforts are to start, as soon as possible, the CE mark trials.”

About MedAutonomic

MedAutonomic is a privately held medtech company dedicated to developing a bioelectric medicine to treat patients with functional diseases of the metabolic syndrome such as type-2 diabetes, hypertension and gastroesophageal reflux disease (GERD). MedAutonomic’s innovative approach is to offer a nonsurgical treatment of these functional diseases with a neuromodulation approach.

MedAutonomic’s Brain NeuroModulation (BNM) device, the Phoenix, is implanted with a digestive endoscope and power is generated without a battery. The device sends a signal directly to the brain to retune an imbalance in the Autonomic Nervous System. For more information, visit www.medautonomic.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005299/en/

CONTACT: MedAutonomic

Paolo Fabris, +39 346 3245963 (Italy)

paolo.fabris@medautonomic.com

or

John Gonzales, 415-377-5653 (USA)

john.gonzales@medautonomic.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: TECHNOLOGY NANOTECHNOLOGY HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES

SOURCE: MedAutonomic

Copyright Business Wire 2018.

PUB: 09/18/2018 07:00 AM/DISC: 09/18/2018 07:01 AM

http://www.businesswire.com/news/home/20180918005299/en

AP RADIO
Update hourly